Meropenem:一个新的碳青霉烯抗生素。

文章的细节

引用

复制到剪贴板

Pryka RD,黑格通用

Meropenem:一个新的碳青霉烯抗生素。

安Pharmacother。1994年9月,28 (9):1045 - 54。

PubMed ID

7803882 (在PubMed

]

文摘

目的:描述然后比较试验性碳青霉烯抗生素,meropenem,只有当前可用抗生素在这个类中,imipenem / cilastatin。数据标识:一个英文搜索使用MEDLINE (1988 - 1993);抽象的31日抗菌药物和化疗跨学科会议上(中华),1991;和抽象的第32中华,1992年。综述了研究选择:所有当前科学出版物的研究设计和质量。重点是放在易感性和药代动力学分析。3期临床试验正在完成,只有在抽象的形式发表。因此,结论推导出关于功效的。结果:Meropenem活跃的广谱革兰氏阳性和阴性的病原体包括beta-lactamase生产商。Meropenem似乎是活跃的两到四倍低于imipenem对抗革兰氏阳性微生物。 Meropenem is two- to fivefold more active against enterobacteriaceae. The two compounds appear to be equally active against Pseudomonas aeruginosa. Pharmacokinetic disposition is also similar for imipenem and meropenem. Meropenem may exhibit greater tissue penetration. Meropenem is not labile to renal hydrolysis and can be administered without a competitive antagonist of dihydropeptidase, such as cilastatin. In clinical trials, meropenem appears to be as safe and effective as imipenem/cilastatin or ceftazidime in the treatment of infections involving soft tissue, urinary tract, upper respiratory tract, abdominal processes, and febrile neutropenic episodes. CONCLUSIONS: Meropenem is comparable to imipenem in terms of in vitro susceptibility pattern and pharmacokinetic disposition. Overall, meropenem seems to offer promise as the second of the carbapenem class of antibiotics. Clinical data are preliminary, and further data are needed.

beplay体育安全吗DrugBank数据引用了这篇文章

药物酶

药物	酶	类	生物	药理作用	行动
Meropenem	Beta-lactamase OXA-10	蛋白质	铜绿假单胞菌	未知的	底物	细节